Author:
Crohns C.,Bauerschlag D.,Maass N.
Publisher
Springer Science and Business Media LLC
Subject
Obstetrics and Gynaecology
Reference19 articles.
1. Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists‘ Group Forbes JF, Cuzick J et al (2008) Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 9:45–53
2. Boccardo F, Rubagotti A, Amoroso D et al (1998) Italian breast cancer adjuvant chemo-hormone therapy cooperative group trials. GROCTA Trials. Recent Results Cancer Res 152:453–470
3. Castiglione-Gertsch M, O’Neill A, Price KN et al (2003) Adjuvant chemotherapy followed by goserelin vs. either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial. J Natl Cancer Inst 17, 95(24):1833–1846
4. Coates AS, Keshaviah A, Thürlimann B et al (2007) Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 10, 25(5):486–492
5. Coombes RC, Kilburn LS, Snowdon CF et al (2007) Survival and safety of exemestane vs. tamoxifen after 2-3 years‘ tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 369:559–570